glp-1 compounding crackdown news october 2025 Alarming rise in weight loss drug overdoses

Did the FDA Ban Compounded Semaglutide and Tirzepatide?

22.46

★★★★☆4.8 (126)

Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders

24.62

★★★★★4.9 (98)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

22.47

★★★★★5.0 (157)

Despite FDA crackdown, unapproved GLP-1s still threaten the industry

22.14

★★★★★4.7 (84)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

27.19

★★★★★4.9 (203)

The FDA is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday

27.42

★★★★★5.0 (176)

National Hispanic Medical Association | After compounded GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and

29.73

★★★★★4.8 (132)